LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS
Application
US20260076962A1
Kind: A1
Mar 19, 2026
Assignee
NImmune Biopharma, Inc.
Inventors
Josep Bassaganya-Riera, Adria Carbo Barrios, Richard Gandour, Julian D. Cooper, Raquel Hontecillas
Abstract
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.
CPC Classifications
A61K 31/496
A61K 31/4184
A61K 31/423
A61K 31/4439
C07C 65/40
C07D 213/69
C07D 213/79
C07D 307/60
C07D 307/68
C07D 401/14
C07D 403/12
C07D 403/14
C07D 413/12
C07D 413/14
Filing Date
2025-11-19
Application No.
19394619